Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Microcirculation. 2020 Apr 26;27(6):e12620. doi: 10.1111/micc.12620

Fig. 1.

Fig. 1.

The σ1 agonist PRE-084 elevates barrier function and decreases permeability of HUVEC monolayers. A. Traces showing the time course of changes in TER of HUVEC treated with the shown concentrations of PRE-084. The TER values were normalized to the time point just prior to treatment with PRE-084 or vehicle control (time = 0 h). B. The individual and mean normalized TER values for each group after 3 hours of PRE-084 or vehicle control treatment are shown. One-Way ANOVA followed by Dunnett’s multiple comparison test was used for analysis. N=4 HUVEC monolayers per group. P values are shown for differences considered significant (p < 0.05). C. Scatter plot showing the difference in HUVEC monolayer permeability to FITC-albumin between 3-h vehicle and 3-h 100 μM PRE-084 treatment. N=17 for control and N=14 for PRE-084. D. Scatter plot showing the difference in permeability to TRITC-dextran between 3-h vehicle and 3-h 100 μM PRE-084 treatment. N=16 for control and N=17 for PRE-084. For panels C and D, unpaired t-tests were used for analysis and P values are shown for each comparison.